<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1256">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04493359</url>
  </required_header>
  <id_info>
    <org_study_id>33575220.9.0000.0068</org_study_id>
    <nct_id>NCT04493359</nct_id>
  </id_info>
  <brief_title>Switch of Renin-Angiotensin System Inhibitors in Patients With Covid-19</brief_title>
  <acronym>SWITCH-COVID</acronym>
  <official_title>Switch or Maintenance of Renin-Angiotensin System Inhibitors in Patients With Covid-19: A Randomized Proof of Concept Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The SWITCH-COVID trial will randomize patients with COVID-19 that are currently using
      renin-angiotensin system inhibitors for treating hypertension to maintain the therapy during
      in-hospital stay or switch the therapy to other antihypertensive classes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients eligible for the study, after signing informed consent will be randomized 1:1 for
      maintenance of renin-angiotensin system inhibitors or switching the antihypertensive therapy
      for other classes according to a pre-specified protocol.

      Patients are going to be followed during hospital stay for evaluation of clinical endpoints.
      Also blood and urine samples will be acquired for evaluation of renin-angiotensin system
      activation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2020</start_date>
  <completion_date type="Anticipated">February 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 14, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Need for ICU or mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Combined of need for ICU or mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>High sensitivity troponin levels and covid-19 severity</measure>
    <time_frame>30 days</time_frame>
    <description>Evaluate correlation between hs-TnT and covid-19 severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACE-2 activity and disease severity</measure>
    <time_frame>30 days</time_frame>
    <description>Evaluate correlation of ACE-2 activity and disease severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACE-2 activity with different Renin-angiotensin system inhibitors</measure>
    <time_frame>30 days</time_frame>
    <description>Evaluate correlation of ACE-2 activity and Renin-angiotensin system inhibitors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood control and acute renal failure</measure>
    <time_frame>30 days</time_frame>
    <description>Evaluate blood pressure control and acute renal failure in each arm (safety)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Covid19</condition>
  <condition>Angiotensin II Receptor Antagonist Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Switch therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renin-angiotensin system inhibitors will be changed for other anti-hypertensive classes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Renin-angiotensin system inhibitors will be kept during in-hospital stay</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Renin-angiotensin system inhibitors</intervention_name>
    <description>switch anti-hypertensive class</description>
    <arm_group_label>Switch therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hypertension in use of renin-angiotensin system inhibitors

          -  Confirmed COVID-19 infection by rt-PCR, serology tests or typical clinical
             presentation and chest CT.

          -  Symptoms onset &lt; 96h

          -  Need for hospitalization

        Exclusion Criteria:

          -  Heart failure

          -  Previous cerebrovascular disease

          -  Previous myocardial infarction

          -  Blood pressure &gt; 180 x 100 mmHg

          -  Need for 3 or more anti-hypertensive classes

          -  Use os spironolactone

          -  Severe pulmonary disease

          -  Contraindication for using other anti-hypertensive classes (calcium channel blockers,
             hydralazine, diuretics or nitrates)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bruno F Caramelli, MD.PHD</last_name>
    <phone>+551126615376</phone>
    <email>bcaramell@usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caio A Tavares, MD</last_name>
    <phone>+551126615376</phone>
    <email>caio.tavares@usp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto do Coração - Incor HCFMUSP</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05403-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Caramelli, MD.PHD</last_name>
      <phone>+551126615376</phone>
      <email>bcaramell@usp.br</email>
    </contact>
    <contact_backup>
      <last_name>Caio A Tavares, MD</last_name>
      <phone>+551126615376</phone>
      <email>caio.tavares@usp.br</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 29, 2020</study_first_submitted>
  <study_first_submitted_qc>July 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2020</study_first_posted>
  <last_update_submitted>July 29, 2020</last_update_submitted>
  <last_update_submitted_qc>July 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Bruno Caramelli</investigator_full_name>
    <investigator_title>MD. PHD.</investigator_title>
  </responsible_party>
  <keyword>covid19</keyword>
  <keyword>ace inhibitors</keyword>
  <keyword>ace2</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Data may be requested for collaboration projects</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

